

To: [redacted] 5.1.2e [redacted] 5.1.2e @trimbos.nl]; [redacted] 5.1.2e [redacted] 5.1.2e @minvws.nl]; [redacted] 5.1.2e -
 BD/DRC/GC [redacted] 5.1.2e @minjenv.nl]
From: [redacted] 5.1.2e)
Sent: Thur 3/26/2020 8:08:54 AM
Subject: RE: COVID-19, drug use and drug-related services in the EU
Received: Thur 3/26/2020 8:08:54 AM

Ha

Prima, en goed om met emcdda contact te houden

Grt

[redacted] 5.1.2e

Van: [redacted] 5.1.2e <[redacted] 5.1.2e @trimbos.nl>
Verzonden: donderdag 26 maart 2020 08:57
Aan: [redacted] 5.1.2e [redacted] <[redacted] 5.1.2e @minvws.nl>; [redacted] 5.1.2e [redacted] <[redacted] 5.1.2e @minvws.nl>; [redacted] 5.1.2e -
 BD/DRC/GC <[redacted] 5.1.2e @minjenv.nl>
Onderwerp: RE: COVID-19, drug use and drug-related services in the EU

Dank je,

We hadden em al gespot. Heel handig want wij waren al op dezelfde toer met kennis vergaren. Gezien onderstaande (gele) aankondiging zal ik nagaan bij het EMCDDA of wij hier ook aan kunnen bijdragen, vanuit onze inventarisaties naar HR, HGUO (uitgaans onderzoek) en online monitoring. We zijn hier als FP nog niet actief bij betrokken, maar ik kan mij voorstellen dat er tijd nodig was om alle acties op een rijtje te zetten.

In addition to our web resources, the EMCDDA are also developing several new initiatives over the next days and weeks. In summary these include encouraging information exchange between our National Drugs Observatories or National Focal Points on this topic; undertaking a series of rapid assessments and studies on effects of COVID-19 on drug markets, drug services, patterns of use and related harms; providing tailored responses to high level queries on COVID-related topics from stakeholders.

Met vriendelijke groet,

dr. [redacted] 5.1.2e
 Head Drug Monitoring & Policy/Reitox Focal Point - Drugs
 [redacted] 5.1.2e

www.trimbos.nl
 Da Costakade 45 - 3521 VS Utrecht
 Postbus 725 - 3500 AS Utrecht
 Disclaimer



From: [redacted] 5.1.2e [redacted] 5.1.2e @minvws.nl]
Sent: donderdag 26 maart 2020 8:36
To: [redacted] 5.1.2e [redacted] <[redacted] 5.1.2e @minvws.nl>; [redacted] 5.1.2e [redacted] <[redacted] 5.1.2e @trimbos.nl>; [redacted] 5.1.2e - BD/DRC/GC
 <[redacted] 5.1.2e @minjenv.nl>
Subject: FW: COVID-19, drug use and drug-related services in the EU

Tkn

[redacted] 5.1.2e

Van: [redacted] 5.1.25.1.2e <[redacted] 5.1.2e @emcdda.europa.eu>
Verzonden: woensdag 25 maart 2020 18:15
Aan: [redacted] 5.1.2e @ana.gov.ro; Hidden - [redacted] 5.1.2e [redacted] <[redacted] 5.1.2e @sgl.moh.gov.cy>; [redacted] 5.1.2e
 ([redacted] 5.1.2e @mscbs.es) <[redacted] 5.1.2e @mscbs.es>; Hidden - [redacted] 5.1.2e [redacted] <[redacted] 5.1.2e @mscbs.es>; [redacted] 5.1.2e

(5.1.2e @bmg.gv.at < 5.1.2e @bmg.gv.at>; 5.1.2e (5.1.2e @ntakd.lt < 5.1.2e @ntakd.lt>;
 5.1.2e (5.1.2e @bmg.bund.de < 5.1.2e @bmg.bund.de>; 5.1.2e
 (5.1.2e @kbpn.gov.pl < 5.1.2e @kbpn.gov.pl>; 5.1.2e (5.1.2e @kbpn.gov.pl
 < 5.1.2e @kbpn.gov.pl>; 5.1.2e (5.1.2e @sicad.min-saude.pt < 5.1.2e @sicad.min-saude.pt>; 5.1.2e
 5.1.2e (5.1.2e @folkhalsomyndigheten.se < 5.1.2e @folkhalsomyndigheten.se>; 5.1.2e
 < 5.1.2e @emcdda.europa.eu>; 5.1.2e (5.1.2e @um.edu.mt < 5.1.2e @um.edu.mt>; Hidden - 5.1.2e
 5.1.2e < 5.1.2e @GOVERNO.IT>; 5.1.2e (5.1.2e @orfk.police.hu < 5.1.2e @orfk.police.hu>; 5.1.2e 5.1.2e
 5.1.2e < 5.1.2e @pm.gouv.fr>; 5.1.2e (5.1.2e @health.gov.sk < 5.1.2e @health.gov.sk>;
 5.1.2e (5.1.2e @sum.dk < 5.1.2e @sum.dk>; 5.1.2e (5.1.2e @ana.gov.ro < 5.1.2e @ana.gov.ro>; 5.1.2e
 5.1.2e (5.1.2e @just.fgov.be < 5.1.2e @just.fgov.be>; 5.1.2e (5.1.2e @sapo.pt
 @sapo.pt>; Hidden - 5.1.2e < 5.1.2e @sicad.min-saude.pt>; 5.1.2e (5.1.2e @gov.si
 @gov.si>; 5.1.2e (5.1.2e @kbpn.gov.pl < 5.1.2e @kbpn.gov.pl>; 5.1.2e (5.1.2e @kbpn.gov.pl
 @kbpn.gov.pl>; 5.1.2e (5.1.2e @ntakd.lt < 5.1.2e @ntakd.lt>; 5.1.2e
 5.1.2e (5.1.2e @ec.europa.eu < 5.1.2e @ec.europa.eu>; 5.1.2e (5.1.2e @hse.ie
 @hse.ie>; 5.1.2e (5.1.2e @vlada.cz < 5.1.2e @vlada.cz>; 5.1.2e
 (5.1.2e @stm.fi < 5.1.2e @stm.fi>; 5.1.2e (5.1.2e @hotmail.com
 @hotmail.com>; 5.1.2e (5.1.2e @primeminister.gr < 5.1.2e @primeminister.gr>; 5.1.2e
 5.1.2e (5.1.2e @health.gov.sk < 5.1.2e @health.gov.sk>; 5.1.2e
 (5.1.2e @gov.se < 5.1.2e @gov.se>; 5.1.2e (5.1.2e @bmg.bund.de
 @bmg.bund.de>; 5.1.2e (5.1.2e @gmail.com < 5.1.2e @gmail.com>; 5.1.2e
 (5.1.2e @otenet.gr < 5.1.2e @otenet.gr>; 5.1.2e (5.1.2e @gmail.com
 @gmail.com>; 5.1.2e (5.1.2e @ccc.brussels < 5.1.2e @ccc.brussels>; 5.1.2e
 (5.1.2e @ec.europa.eu < 5.1.2e @ec.europa.eu>; 5.1.2e (5.1.2e @uredzadroge.hr
 @uredzadroge.hr>; 5.1.2e (5.1.2e @spkc.gov.lv < 5.1.2e @spkc.gov.lv>; 5.1.2e
 5.1.2e (5.1.2e @biotech.um.edu.mt < 5.1.2e @biotech.um.edu.mt>; 5.1.2e (5.1.2e @ec.europa.eu
 @ec.europa.eu>; 5.1.2e (5.1.2e @ana.gov.ro < 5.1.2e @ana.gov.ro>;
 5.1.2e (5.1.2e @ana.gov.ro < 5.1.2e @ana.gov.ro>; 5.1.2e (5.1.2e @ec.europa.eu
 @ec.europa.eu>; Hidden - 5.1.2e < 5.1.2e @ms.etat.lu>; 5.1.2e (5.1.2e @stm.fi
 @stm.fi>; 5.1.2e (5.1.2e @sm.ee < 5.1.2e @sm.ee>; 5.1.2e
 5.1.2e (5.1.2e @primeminister.gr < 5.1.2e @primeminister.gr>; 5.1.2e (5.1.2e @otenet.gr
 @otenet.gr>; 5.1.2e (5.1.2e @siseministeerium.ee < 5.1.2e @siseministeerium.ee>; PETERSEN Lars
 (5.1.2e @sum.dk < 5.1.2e @sum.dk>; 5.1.2e (5.1.2e @uredzadroge.hr < 5.1.2e @uredzadroge.hr>; 5.1.2e
 5.1.2e (5.1.2e @gov.si < 5.1.2e @gov.si>; 5.1.2e (5.1.2e @bmg.gv.at
 @bmg.gv.at>; 5.1.2e (5.1.2e @ms.etat.lu < 5.1.2e @ms.etat.lu>; 5.1.2e
 (5.1.2e @pm.gouv.fr < 5.1.2e @pm.gouv.fr>; 5.1.2e (5.1.2e @ncpha.government.bg
 @ncpha.government.bg>; 5.1.2e (5.1.2e @minvws.nl < 5.1.2e @minvws.nl>; 5.1.2e
 (5.1.2e @cytanet.com.cy < 5.1.2e @cytanet.com.cy>; 5.1.2e (5.1.2e @police.gov.cy < 5.1.2e @police.gov.cy>;
 5.1.2e (5.1.2e @governo.it < 5.1.2e @governo.it>; 5.1.2e (5.1.2e @palazzochigi.it < 5.1.2e @palazzochigi.it>;
 5.1.2e (5.1.2e @ec.europa.eu < 5.1.2e @ec.europa.eu>; 5.1.2e (5.1.2e @emmi.gov.hu
 @emmi.gov.hu>; 5.1.2e 5.1.2e (5.1.2e @vlada.cz < 5.1.2e @vlada.cz>; 5.1.2e
 (5.1.2e @health.gov.ie < 5.1.2e @health.gov.ie>; 5.1.2e (5.1.2e @resad.cz < 5.1.2e @resad.cz>; 5.1.2e
 (5.1.2e @ncpha.government.bg < 5.1.2e @ncpha.government.bg>; BREDESEN Hege Christina (5.1.2e @hod.dep.no
 @hod.dep.no>; Hidden - 5.1.2e < 5.1.2e @egm.gov.tr>; 5.1.2e (5.1.2e @hod.dep.no < 5.1.2e @hod.dep.no > 5.1.2e
 5.1.2e @hod.dep.no>; 5.1.2e (5.1.2e @hod.dep.no < 5.1.2e @hod.dep.no>; Hidden - 5.1.2e
 5.1.2e @egm.gov.tr>; Hidden - 5.1.2e < 5.1.2e @egm.gov.tr>; 5.1.2e
 (5.1.2e @fhi.no < 5.1.2e @fhi.no>; Hidden - 5.1.2e
 (5.1.2e @sciensano.be>; 5.1.2e (5.1.2e @who.int < 5.1.2e @who.int>; 5.1.2e
 5.1.2e @unodc.org < 5.1.2e @unodc.org>; 5.1.2e (5.1.2e @coe.int < 5.1.2e @coe.int>

Onderwerp: COVID-19, drug use and drug-related services in the EU

Dear members of the Management Board,

First of all I would like to express our full support to the EU Member States, to the Commission and our sister Agencies for their intensive efforts and activities in the reaction to the COVID-19 epidemic. At a time when the European project is the object of frequently unfair criticisms, it is important to make our actions more visible to EU citizens. The EMCDDA stands together with EU Institutions and Bodies to deliver added value for its citizens

and to defend/promote our achievements, and to contribute more than ever to “a Healthier and More Secure Europe”.

In that context, it is my pleasure to provide you with an update on some of the work EMCDDA colleagues are engaged in with regard to the COVID epidemic and challenges raised for drug services and people who use drugs.

An internal cross unit task force has prioritised the development of a landing page on the topic of COVID-19 and drugs which has been launched today.

COVID-19 update in html format:

<http://www.emcdda.europa.eu/publications/topic-overviews/covid-19-and-people-who-use-drugs>

COVID-19 update in PDF format:

http://www.emcdda.europa.eu/publications/topic-overviews/catalogue/covid-19-and-people-who-use-drugs_en

News item:

http://www.emcdda.europa.eu/news/2020/emcdda-publishes-update-on-the-implications-of-COVID-19-for-people-who-use-drugs-and-for-drug-service-providers_en

We recognise that the main response actors in this crisis are agencies with a remit for infectious diseases and public health such as the WHO and ECDC and we see our role primarily as acting as a hub or conduit for people seeking access to reliable informations and resources that focus on drug-related issues. We aim to do this by ensuring a strong web presence and providing access to a range of emerging resources and guidelines which will be useful for those working in front line drug services.

Today we launch the first briefing on COVID-19 and drugs on our web and this will soon be updated with links to new resources and Frequently Asked Questions compiled on the basis of consultation with our colleagues and networks in the field across Europe. We are aware that drug services, in common with other health services, are experiencing serious problems with staff, medication and equipment shortages, and core interventions and the continuity of care for drug using clients is under threat with the reported closure of services occurring in many countries. While most of the challenges they meet are not specific to drugs use, some others are, such as the conditions to access to substitution treatment, emerging needs to initiate substitution treatment caused by a reduced availability of drugs, or the challenges to maintain harm reduction interventions that save lives.

In addition to our web resources, the EMCDDA are also developing several new initiatives over the next days and weeks. In summary these include encouraging information exchange between our National Drugs Observatories or National Focal Points on this topic; undertaking a series of rapid assessments and studies on effects of COVID-19 on drug markets, drug services, patterns of use and related harms; providing tailored responses to high level queries on COVID-related topics from stakeholders.

We remain at your entire disposal for any additional information or service that you would require.

Thank you for your support

Alexis

5.1.2e

Director

EMCDDA

"Contributing to a Healthier and More Secure Europe"



5.1.2 5.1.2e

Senior policy officer to the Management Board
Executive office

5.1.2e

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal • www.emcdda.europa.eu

This message and any attachment contain information which may be sensitive or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.

Please consider the impact on the environment before printing this email.